GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Heres a quick look at how they stack up: So, while L-Citrulline keeps it simple, Citrulline Malate brings a little extra to the party
The company is not alone
Image Credit: While of My Desk / Shutterstock In a recent study published in the journal Scientific Reports , a group of researchers evaluated whether maternal exposure to glucagon-like peptide-1 (GLP-1) receptor agonists during the periconceptional period or pregnancy is associated with congenital malformations or other adverse pregnancy outcomes
Is tesamorelin FDA-approved
GLP-1 medications like Ozempic, Wegovy, Zepbound, or Mounjaro slow your digestion and suppress your appetite